These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 22726096)

  • 1. Personalized prophylaxis.
    Collins PW
    Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C; Watts RG
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
    Collins PW; Fischer K; Morfini M; Blanchette VS; Björkman S;
    Haemophilia; 2011 Jan; 17(1):2-10. PubMed ID: 20731726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
    Shapiro AD; Korth-Bradley J; Poon MC
    Haemophilia; 2005 Nov; 11(6):571-82. PubMed ID: 16236106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations in individualizing prophylaxis in patients with haemophilia A.
    Valentino LA
    Haemophilia; 2014 Sep; 20(5):607-15. PubMed ID: 24712891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis in the haemophilia population.
    Blanchette VS
    Haemophilia; 2010 Jul; 16 Suppl 5():181-8. PubMed ID: 20590879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Models of prophylaxis.
    Berntorp E; Fischer K; Miners A
    Haemophilia; 2012 Jul; 18 Suppl 4():136-40. PubMed ID: 22726097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia.
    Thornburg CD; Pipe SW
    Haemophilia; 2006 Mar; 12(2):198-9. PubMed ID: 16476098
    [No Abstract]   [Full Text] [Related]  

  • 14. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
    Walsh CE; Valentino LA
    Haemophilia; 2009 Sep; 15(5):1014-21. PubMed ID: 19493018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
    Nagel K; Walker I; Decker K; Chan AK; Pai MK
    Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of arthropathy in haemophilia: prophylaxis.
    Santagostino E; Mancuso ME
    Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañes M; Paez A
    Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.